phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»10.37489/2587-7836-2025-3-3-8ZRAIYQphkinetica-468Research ArticleПОИСК НОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВNEW DRUGS DISCOVERYГК-2 — дипептидный миметик 4-й петли NGF — увеличивает содержание BDNF и активен на клеточной модели болезни ПаркинсонаGK-2 — dipeptide mimetic of 4th loop NGF increases the level of BDNF and is active in the cell model of Parkinson's diseasehttps://orcid.org/0000-0002-9309-4872АнтиповаТ. А.AntipovaТ. A.

Антипова Татьяна Алексеевна — к.б.н., в.н.с. лаборатории молекулярной фармакологии

Москва

Tatyana A. Antipova — PhD, Cand. Sci. (Biology), Leading researcher, Molecular pharmacology laboratory

Moscow

antipova_ta@academpharm.ruhttps://orcid.org/0000-0003-4584-746XНиколаевС. В.NikolaevS. V.

Николаев Сергей Владимирович — н.с. лаборатории молекулярной фармакологии

Москва

Sergey V. Nikolaev — Research Scientist Molecular pharmacology laboratory

Moscow

nikolaev_sv@academpharm.ruФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»РоссияFederal research center for innovator and emerging biomedical and pharmaceutical technologiesRussian Federation2025261220250338Copyright © Антипова Т.А., Николаев С.В., 20252025Антипова Т.А., Николаев С.В.Antipova Т.A., Nikolaev S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/468

NGF в концентрации 100 нг/мл при добавлении за 24 ч до 6-гидроксидофамина и после повреждения полностью предотвращал развитие повреждающего действия нейротоксина. Дипептид ГК-2 в концентрации 10−5 М, подобно NGF, проявлял защитный эффект на клеточной модели болезни Паркинсона. По данным Вестерн-блот анализа NGF через 24 ч после внесения увеличивал содержание BDNF в клетках НТ-22 в 1,6 раза по сравнению с контролем, а дипептид ГК-2 в концентрации 10−8 М — в 1,4 раза по сравнению с контролем.

NGF at a concentration of 100 ng / ml when added 24 hours before 6-OHDA and after damage completely prevented the development of the damaging effect of neurotoxin. Dipeptide GK-2 at a concentration of 10−5 M, similar to NGF, showed a protective effect on the cellular model of Parkinson's disease. According to the Western blot analysis NGF increased the level of BDNF in the HT-22 cells 1.6 times compared to the control, and dipeptide GK-2 at a concentration of 10−8 M — 1.4 times compared to the control.

болезнь Паркинсона6-гидроксидофаминнейропротекцияNGFBDNFдимерный дипептидный миметик ГК-2Parkinson's disease6-hydroxydopamineneuroprotectionNGFBDNFdimeric dipeptide mimetic GK-2ReferencesПатент РФ на изобретение №2410392C2/ 27.01.11 Середенин (RU) С.Б., Гудашева Т.А. Дипептидные миметики нейротрофинов NGF и BDNF. Доступно по: https://patents.google.com/patent/RU2410392C2/ru. Ссылка активна на 15.09.2025.Patent Russ. №RU2410392C2/ 27.01.11 [Seredenin SB, Gudasheva TA. Dipeptide mimetics of NGF and BDNF neurotrophins. (In Russ.). Доступно по: https://patents.google.com/patent/RU2410392C2/ru. Ссылка активна на 15.09.2025.Cереденин С.Б., Гудашева Т.А. Создание фармакологически активной малой молекулы, обладающей свойствами фактора роста нервов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(6):63 70. doi: 10.17116/jnevro20151156163-70.Seredenin SB, Gudasheva TA. The development of a pharmacologically active low-molecular mimetic of the nerve growth factor. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(6):63 70. (In Russ.). doi: 10.17116/jnevro20151156163-70.Поварнина П.Ю., Гудашева Т.А., Воронцова О.Н., и др. Антипаркинсонические свойства дипептидного миметика фактора роста нервов ГК-2 в экспериментах in vivo. Бюллетень экспериментальной биологии и медицины. 2011;151(6);634-637. EDN: NXLJAXPovarnina PYu, Gudasheva TA, Vorontsova ON, et al. Antiparkinsonian properties of a nerve GROWTH FACTOR dipeptide mimetic GK-2 in vivo experiments. Bulletin of experimental biology and medicine. 2011;151(6);634-637. (In Russ.). EDN: NXLJAXBerg-von der Emde K, Dees WL, Hiney JK, et al. Neurotrophins and the neuroendocrine brain: different neurotrophins sustain anatomically and functionally segregated subsets of hypothalamic dopaminergic neurons. J Neurosci. 1995 Jun;15(6):4223-37. doi: 10.1523/JNEUROSCI.15-06-04223.1995.Berg-von der Emde K, Dees WL, Hiney JK, et al. Neurotrophins and the neuroendocrine brain: different neurotrophins sustain anatomically and functionally segregated subsets of hypothalamic dopaminergic neurons. J Neurosci. 1995 Jun;15(6):4223-37. doi: 10.1523/JNEUROSCI.15-06-04223.1995.Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004 Sep;22(3):123-31. doi: 10.1080/08977190410001723308.Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004 Sep;22(3):123-31. doi: 10.1080/08977190410001723308.Сазонова Н.М., Тарасюк А.В., Курилов Д.В., и др. Синтез димерного дипептидного миметика фактора роста нервов ГК-2, потенциального нейропротективного препарата. Химико-фармацевтический журнал. 2015;49(7):10-19.Sazonova NM, Tarasyuk AV, Kurilov DV, et al. Synthesis of two-dimensional dipeptide mimetic of nerve growth factor: new potential neuroprotective drug. Pharmaceutical Chemistry Journal. 2015;49(7):10-19. (In Russ.).Антипова Т.А., Гудашева Т.А., Середенин С.Б. Исследование in vitro нейропротективных свойств нового оригинального миметика фактора роста нервов ГК-2. Бюллетень экспериментальной биологии и медицины. 2010;150(11):538-541. EDN: MVUWEPAntipova TA, Gudasheva TA, Seredenin SB. In vitro study of neuroprotective properties of GK-2, a new original nerve growth factor mimetic. Bulletin of experimental biology and medicine. 2010;150(11):538-541. (In Russ.). EDN: MVUWEPRiveles K, Huang LZ, Quik M. Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells. Neurotoxicology. 2008 May;29(3):421-7. doi: 10.1016/j.neuro.2008.02.001.Riveles K, Huang LZ, Quik M. Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells. Neurotoxicology. 2008 May;29(3):421-7. doi: 10.1016/j.neuro.2008.02.001.Ueda Y, Walsh E, Nakanishi H, Yoshida K. A colorimetric assay method for the evaluation of neurotrophic activity in vitro. Neurosci Lett. 1994 Jan 3; 165(1-2):203-7. doi: 10.1016/0304-3940(94)90745-5.Ueda Y, Walsh E, Nakanishi H, Yoshida K. A colorimetric assay method for the evaluation of neurotrophic activity in vitro. Neurosci Lett. 1994 Jan 3; 165(1-2):203-7. doi: 10.1016/0304-3940(94)90745-5.Alam A. A model for formulation of protein assay. Anal Biochem. 1992 May 15;203(1):121-6. doi: 10.1016/0003-2697(92)90051-8.Alam A. A model for formulation of protein assay. Anal Biochem. 1992 May 15;203(1):121-6. doi: 10.1016/0003-2697(92)90051-8.Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979 Sep;76(9):4350-4. doi: 10.1073/pnas.76.9.4350.Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA. 1979 Sep;76(9):4350-4. doi: 10.1073/pnas.76.9.4350.Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017 Jan 24;12(1):10. doi: 10.1186/s13024-017-0149-0.Xicoy H, Wieringa B, Martens GJ. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017 Jan 24;12(1):10. doi: 10.1186/s13024-017-0149-0.Kume T, Kawato Y, Osakada F, et al. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. Neurosci Lett. 2008 Oct 10;443(3):199-203. doi: 10.1016/j.neulet.2008.07.079.Kume T, Kawato Y, Osakada F, et al. Dibutyryl cyclic AMP induces differentiation of human neuroblastoma SH-SY5Y cells into a noradrenergic phenotype. Neurosci Lett. 2008 Oct 10;443(3):199-203. doi: 10.1016/j.neulet.2008.07.079.Arun P, Madhavarao CN, Moffett JR, Namboodiri AM. Antipsychotic drugs increase N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells. J Neurochem. 2008 Aug;106(4):1669-80. doi: 10.1111/j.1471-4159.2008.05524.x.Arun P, Madhavarao CN, Moffett JR, Namboodiri AM. Antipsychotic drugs increase N-acetylaspartate and N-acetylaspartylglutamate in SH-SY5Y human neuroblastoma cells. J Neurochem. 2008 Aug;106(4):1669-80. doi: 10.1111/j.1471-4159.2008.05524.x.Chong PN, Sangu M, Huat TJ, et al. Trkb-IP3 Pathway Mediating Neuroprotection in Rat Hippocampal Neuronal Cell Culture Following Induction of Kainic Acid. Malays J Med Sci. 2018 Nov;25(6):28-45. doi: 10.21315/mjms2018.25.6.4.Chong PN, Sangu M, Huat TJ, et al. Trkb-IP3 Pathway Mediating Neuroprotection in Rat Hippocampal Neuronal Cell Culture Following Induction of Kainic Acid. Malays J Med Sci. 2018 Nov;25(6):28-45. doi: 10.21315/mjms2018.25.6.4.Yoo JM, Lee BD, Sok DE, et al. Neuroprotective action of N-acetyl serotonin in oxidative stress-induced apoptosis through the activation of both TrkB/CREB/BDNF pathway and Akt/Nrf2/Antioxidant enzyme in neuronal cells. Redox Biol. 2017 Apr;11:592-599. doi: 10.1016/j.redox.2016.12.034.Yoo JM, Lee BD, Sok DE, et al. Neuroprotective action of N-acetyl serotonin in oxidative stress-induced apoptosis through the activation of both TrkB/CREB/BDNF pathway and Akt/Nrf2/Antioxidant enzyme in neuronal cells. Redox Biol. 2017 Apr;11:592-599. doi: 10.1016/j.redox.2016.12.034.Yu SJ, Grider JR, Gulick MA, et al. Up-regulation of brain-derived neurotrophic factor is regulated by extracellular signal-regulated protein kinase 5 and by nerve growth factor retrograde signaling in colonic afferent neurons in colitis. Exp Neurol. 2012 Dec;238(2):209-17. doi: 10.1016/j.expneurol.2012.08.007.Yu SJ, Grider JR, Gulick MA, et al. Up-regulation of brain-derived neurotrophic factor is regulated by extracellular signal-regulated protein kinase 5 and by nerve growth factor retrograde signaling in colonic afferent neurons in colitis. Exp Neurol. 2012 Dec;238(2):209-17. doi: 10.1016/j.expneurol.2012.08.007.R. Levi-Montalcini. The Saga of the Nerve Growth Factor: Preliminary Studies, Discovery, Further Development. Singapore: World Scientific; 1997.R. Levi-Montalcini. The Saga of the Nerve Growth Factor: Preliminary Studies, Discovery, Further Development. Singapore: World Scientific; 1997.Salehi A, Delcroix JD, Mobley WC. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci. 2003 Feb;26(2):73-80. doi: 10.1016/S0166-2236(02)00038-3.Salehi A, Delcroix JD, Mobley WC. Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci. 2003 Feb;26(2):73-80. doi: 10.1016/S0166-2236(02)00038-3.Lazo OM, Mauna JC, Pissani CA, et al. Axotomy-induced neurotrophic withdrawal causes the loss of phenotypic differentiation and downregulation of NGF signalling, but not death of septal cholinergic neurons. Mol Neurodegener. 2010 Jan 19;5:5. doi: 10.1186/1750-1326-5-5.Lazo OM, Mauna JC, Pissani CA, et al. Axotomy-induced neurotrophic withdrawal causes the loss of phenotypic differentiation and downregulation of NGF signalling, but not death of septal cholinergic neurons. Mol Neurodegener. 2010 Jan 19;5:5. doi: 10.1186/1750-1326-5-5.

The authors declare that there are no conflicts of interest present.